---
title: "Bicara Therapeutics Inc. (BCAX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BCAX.US.md"
symbol: "BCAX.US"
name: "Bicara Therapeutics Inc."
industry: "Biotechnology"
datetime: "2026-05-20T03:03:47.438Z"
locales:
  - [en](https://longbridge.com/en/quote/BCAX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BCAX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BCAX.US.md)
---

# Bicara Therapeutics Inc. (BCAX.US)

## Company Overview

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.bicara.com](https://www.bicara.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -8.37 | 427 | - | - | - |
| PB | 2.56 | 230 | 2.68 | 2.14 | 1.37 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-12T04:00:00.000Z

Total Analysts: **14**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 57% |
| Overweight | 3 | 21% |
| Hold | 3 | 21% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 20.03 |
| Highest Target | 46.00 |
| Lowest Target | 16.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BCAX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BCAX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BCAX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BCAX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**